

Mitelos announces 1.5 millionth Otiblock® unit sold

Otiblock came to market in 2016 for the first time and will be available in 15 countries on 4 continents by the end of 2021.

June 7th, 2021.- Mitelos is delighted to announce that it has reached 1.5 million Otiblock® units sold. This medical device first came to the market in 2016 and will be available in 15 countries on 4 continents by the end of 2021.

Otiblock® was developed with the physiology of the outer ear in mind, not only in terms of its mechanism of action, but also with the aim of not altering this physiology during the process of removing earwax plugs.

Otic cerumen accumulation is a highly prevalent problem that not only causes bothersome local symptoms but also prevents correct tympanic visualisation (this is particularly relevant in children) and causes partial hearing loss, which in the elderly can lead to cognitive impairment.

In addition to being oil-free to make the product cleaner and more pleasant, and not hindering instrumentation in the event that manual removal of the earplug by the healthcare professional is required, the formulation of Otiblock® favours the maintenance of the physiological pH of the ear. It is well known that an alteration of the local pH is a risk factor that can trigger an infection.

Otiblock® comes in 45ml spray and 18ml dropper, which allow to administer the right dose and can be used above 3 years.

About Mitelos

Mitelos is an independent private company that develops, registers and licenses health products and dietary supplements. Mitelos also provides business development services to third parties in order to help clients achieve their growth-related goals.

For more information, visit www.mitelos.com

Contact:

Joaquim Colomé

jcolome@mitelos.com

Tel.: +34 935 481 858